Tag Archives: ACRS

Hot Undervalued Stocks To Buy Right Now

Quanta Services (NYSE:PWR) announced that its Board of Directors has approved a share repurchase program, which permits the company to buyback $500.00 million in shares on Tuesday, September 4th. This buyback authorization permits the construction company to purchase up to 9.7% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

PWR has been the subject of a number of recent research reports. ValuEngine downgraded shares of Quanta Services from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Quanta Services from a “sell” rating to a “hold” rating in a report on Monday, July 23rd. Finally, B. Riley lifted their price target on shares of Quanta Services from $52.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, August 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Quanta Services presently has an average rating of “Buy” and an average target price of $46.30.

Hot Undervalued Stocks To Buy Right Now: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Max Byerly]

    Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

  • [By Shane Hupp]

    Aclaris Therapeutics Inc (NASDAQ:ACRS) Director Stephen A. Tullman bought 6,600 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, August 23rd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $99,000.00. Following the acquisition, the director now owns 170,357 shares of the company’s stock, valued at $2,555,355. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Undervalued Stocks To Buy Right Now: Odyssey Marine Exploration Inc.(OMEX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    News stories about Odyssey Marine Exploration (NASDAQ:OMEX) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Odyssey Marine Exploration earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the business services provider an impact score of 46.3184749361846 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Money Morning Staff Reports]

    After looking at this week’s penny stock gainers, we’ll give you that leg up with one of our top-rated penny stocks from our proprietary stock ranking system…

    Penny Stock Current Share Price (March 26) Last Week’s Gain
    Cartesian Inc. (OTCMKTS: CRTN) $0.39 170.69%
    Odyssey Marine Exploration Inc. (Nasdaq: OMEX) $8.76 135.90%
    iFresh Inc. (Nasdaq: IFMK) $8.25 64.64%
    China Auto Logistics Inc. (Nasdaq: CALI) $4.68 47.43%
    National American University Holdings Inc. (Nasdaq: NAUH) $1.20 39.29%
    Document Security Systems Inc. (NYSE: DSS) $1.58 33.91%
    Blonder Tongue Labs Inc. (NYSE: BDR) $0.77 33.90%
    CareDx Inc. (Nasdaq: CDNA) $7.49 29.88%
    Mediwound Ltd. (Nasdaq: MDWD) $5.10 26.51%
    New York & Co. Inc. (NYSE: NWY) $3.37 26.35%

    Don’t Miss This Shot at a $78,000 Windfall: This tiny firm is about to make the entire world wire-free. As its game-changing technology revolutionizes the global power structure, its stock could hand investors a massive return. Learn more…

  • [By Joseph Griffin]

    Kenon (NYSE: KEN) and Odyssey Marine Exploration (NASDAQ:OMEX) are both small-cap utilities companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

  • [By Max Byerly]

    Odyssey Marine Exploration (NASDAQ: OMEX) and Teekay Offshore Partners (NYSE:TOO) are both small-cap transportation companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Hot Undervalued Stocks To Buy Right Now: Globalstar Inc.(GSAT)

Advisors’ Opinion:

  • [By Paul Ausick]

    Globalstar Inc. (NASDAQ: GSAT) fell by about 3.6% Thursday to post a new 52-week low of $0.53 after closing at $0.55 on Wednesday. The 52-week high is $2.59. Volume of about 5.2 million was around 30% above the daily average. The company had no specific news and shares are on now track to post a gain of around 3% for the day.

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 2% Friday and posted a new 52-week low of $0.49 after closing Thursday at $0.50. The stock’s 52-week high is $2.30. Volume totaled about 4.2 million, almost 20% below the daily average of around  5.4 million. The company had no specific news.

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 6% Tuesday and posted a new 52-week low of $0.47 after closing Monday at $0.50. The stock’s 52-week high is $2.30. Volume totaled about 4.3 million, about 20% below the daily average of around  5.4 million. The company had no specific news.

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 12.5% Tuesday and posted a new 52-week low of $0.77 after closing Monday at $0.88. The stock’s 52-week high is $2.59. Volume was about 70% above the daily average of around 3.7 million shares. The had no specific news.

  • [By Paul Ausick]

    Globalstar Inc. (NYSEAMERICAN: GSAT) traded down about 5.9% Monday and posted a new 52-week low of $0.48 after closing Friday at $0.51. The stock’s 52-week high is $2.30. Volume totaled about 4.4 million, about 20% below the daily average of around  5.4 million. The company had no specific news.

  • [By Anders Bylund]

    Shares of Globalstar (NYSEMKT:GSAT) had a wild ride in April. By the end of the month, the stock had fallen 11% lower, according to data from S&P Global Market Intelligence.

Hot Undervalued Stocks To Buy Right Now: CompX International Inc.(CIX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    CI Financial Corp (TSE:CIX)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$23.92 and last traded at C$23.92, with a volume of 138823 shares traded. The stock had previously closed at C$24.14.

  • [By Joseph Griffin]

    CI Financial (TSE:CIX) had its price objective decreased by analysts at TD Securities from C$25.00 to C$24.00 in a research note issued to investors on Friday. TD Securities’ price target would indicate a potential upside of 12.36% from the stock’s previous close.

  • [By Shane Hupp]

    CI Financial (TSE:CIX) will issue its quarterly earnings data before the market opens on Thursday, May 10th. Analysts expect the company to announce earnings of C$0.63 per share for the quarter.

Hot Undervalued Stocks To Buy Right Now: Petroleo Brasileiro S.A.- Petrobras(PBR)

Advisors’ Opinion:

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, decreased to 47.04 million shares from the previous 49.09 million. The stock traded at $15.40 a share, in a 52-week range of $9.02 to $17.20. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, increased to 34.35 million shares from the previous 31.85 million. The stock traded at $13.40 a share, in a 52-week range of $7.61 to $14.93. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, decreased to 42.60 million shares from the previous 43.43 million. The stock traded at $10.52 a share, in a 52-week range of $9.02 to $17.20. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, increased to 63.71 million shares from the previous 47.03 million. The stock traded at $9.91 a share, in a 52-week range of $7.64 to $17.20. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Jon C. Ogg]

    Petróleo Brasileiro S.A. (NYSE: PBR), or Petrobras, was downgraded to Underperform from Market Perform at Raymond James. Its American depositary shares closed down 0.5% at $14.30 on Friday.

  • [By Joseph Griffin]

    Shares of PETROLEO BRASIL/ADR (NYSE:PBR) traded up 5.3% during trading on Friday . The stock traded as high as $11.48 and last traded at $11.34. 37,383,100 shares changed hands during trading, an increase of 60% from the average session volume of 23,307,816 shares. The stock had previously closed at $10.77.

Hot Undervalued Stocks To Buy Right Now: UniSource Energy Corporation(UNS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Uni Select (TSE:UNS) had its price target lifted by investment analysts at Macquarie from C$24.00 to C$25.00 in a report released on Wednesday. Macquarie’s price objective suggests a potential upside of 18.32% from the stock’s current price.

  • [By Max Byerly]

    Uni Select (TSE:UNS)‘s stock had its “hold” rating restated by equities research analysts at TD Securities in a report issued on Friday. They currently have a C$24.00 price objective on the stock. TD Securities’ price target points to a potential upside of 8.21% from the stock’s current price.

Top 10 High Tech Stocks To Watch Right Now

What happened

After the Food and Drug Administration greenlit the use of software that can suspend insulin when its insulin pump is used in conjunction with DexCom’s (NASDAQ:DXCM) continuous glucose monitor (CGM), shares of Tandem Diabetes Care (NASDAQ:TNDM) are rallying 10.2% at 12:45 p.m. EDT on Friday.

So what

Historically, diabetes patients can spend up to 70% of their day outside their desired blood glucose range, and as a result, they’re at risk of seeing their disease progress to a point where it causes life-threatening complications.

IMAGE SOURCE: GETTY IMAGES.

In a bid to better control blood sugar levels, doctors and patients are increasingly embracing monitors that can track blood sugar levels in real time and pumps that provide background insulin. The use of these systems together can conceivably automate insulin dosing. However, software that can predict future blood sugar levels to avoid the risk of hypoglycemia, or ultra-low levels of blood sugar that can be life-threatening, is necessary for that to happen.

Top 10 High Tech Stocks To Watch Right Now: Echo Global Logistics, Inc.(ECHO)

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Echo Global Logistics Inc  (NASDAQ:ECHO)Q4 2018 Earnings Conference CallFeb. 06, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Echo Global Logistics (ECHO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Koch Industries Inc. purchased a new stake in shares of Echo Global Logistics, Inc. (NASDAQ:ECHO) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 11,361 shares of the transportation company’s stock, valued at approximately $314,000.

  • [By Ethan Ryder]

    Forward Air (NASDAQ: FWRD) and Echo Global Logistics (NASDAQ:ECHO) are both small-cap transportation companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Top 10 High Tech Stocks To Watch Right Now: Shutterfly Inc.(SFLY)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Shutterfly, Inc. (NASDAQ:SFLY) has received an average rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $91.50.

  • [By Ethan Ryder]

    American Century Companies Inc. lifted its holdings in shares of Shutterfly, Inc. (NASDAQ:SFLY) by 208.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 324,834 shares of the technology company’s stock after buying an additional 219,679 shares during the quarter. American Century Companies Inc. owned about 0.98% of Shutterfly worth $29,245,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Shutterfly (SFLY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Shutterfly, Inc. (NASDAQ:SFLY) insider Lisa Blackwood-Kapral sold 3,742 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $46.26, for a total transaction of $173,104.92. Following the transaction, the insider now directly owns 1,625 shares in the company, valued at approximately $75,172.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

Top 10 High Tech Stocks To Watch Right Now: AxoGen, Inc.(AXGN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    State Board of Administration of Florida Retirement System boosted its holdings in AxoGen, Inc Common Stock (NASDAQ:AXGN) by 17.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,103 shares of the medical equipment provider’s stock after buying an additional 3,490 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.06% of AxoGen, Inc Common Stock worth $1,161,000 at the end of the most recent quarter.

  • [By Shane Hupp]

    AxoGen, Inc (NASDAQ:AXGN) – Analysts at William Blair raised their Q2 2018 earnings estimates for AxoGen in a research report issued on Monday, May 14th. William Blair analyst K. Krum now expects that the medical equipment provider will post earnings per share of ($0.04) for the quarter, up from their prior forecast of ($0.05). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for AxoGen’s Q4 2018 earnings at ($0.03) EPS and FY2018 earnings at ($0.25) EPS.

  • [By Joseph Griffin]

    These are some of the media stories that may have impacted Accern’s analysis:

    Get AxoGen alerts:

    Analysts Anticipate AxoGen, Inc (AXGN) Will Announce Earnings of -$0.06 Per Share (americanbankingnews.com) The SVP Sales of AxoGen (NASDAQ: AXGN) is Selling Shares (analystratings.com) BRIEF-Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As Chairman (reuters.com) AxoGen, Inc (AXGN) SVP Shawn F. Mccarrey Sells 10,000 Shares (americanbankingnews.com) Global Nerve Repair Biomateria Market Report 2018-2023 -Axogen, Integra, Synovis, Collagen Matrix, Polyganics … (talkdailynews.com)

    AxoGen opened at $43.95 on Monday, Marketbeat reports. AxoGen has a fifty-two week low of $13.95 and a fifty-two week high of $46.00. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.81 and a current ratio of 3.32. The company has a market cap of $1.52 billion, a P/E ratio of -141.77 and a beta of -0.04.

Top 10 High Tech Stocks To Watch Right Now: NIC Inc.(EGOV)

Advisors’ Opinion:

  • [By Max Byerly]

    Shares of NIC Inc. (NASDAQ:EGOV) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

  • [By Joseph Griffin]

    Media headlines about NIC (NASDAQ:EGOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NIC earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the software maker an impact score of 44.2220263592641 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Joseph Griffin]

    NIC Inc. (NASDAQ:EGOV) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

  • [By Brian Feroldi]

    NIC (NASDAQ:EGOV), a provider of specialty software services primarily focused on government agencies, reported its fourth-quarter results last week. Revenue and net income both took a step back during the quarter due to the loss of revenue from its largest customer.

  • [By Brian Feroldi]

    NIC (NASDAQ:EGOV), a leading provider of digital government services, reported its second-quarter results on Aug. 1. Increased usage of the company’s services helped drive modest revenue growth during the quarter. Management took full advantage of the increased scale, which drove a 31% gain on the bottom line.

  • [By Logan Wallace]

    BidaskClub upgraded shares of NIC (NASDAQ:EGOV) from a buy rating to a strong-buy rating in a research note published on Friday morning.

    Several other research firms also recently commented on EGOV. Zacks Investment Research downgraded NIC from a hold rating to a sell rating in a report on Monday, January 8th. ValuEngine downgraded NIC from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Barrington Research restated a hold rating on shares of NIC in a report on Monday, April 30th. TheStreet downgraded NIC from a b- rating to a c rating in a report on Thursday, March 8th. Finally, Loop Capital decreased their price objective on NIC to $14.00 and set a hold rating for the company in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.33.

Top 10 High Tech Stocks To Watch Right Now: Live Ventures Incorporated(LIVE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Live Ventures (NASDAQ: LIVE) and PennantPark Investment (NASDAQ:PNNT) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

  • [By Stephan Byrd]

    Live Stars (CURRENCY:LIVE) traded up 2.3% against the dollar during the 24 hour period ending at 23:00 PM Eastern on June 25th. Over the last seven days, Live Stars has traded down 10.1% against the dollar. One Live Stars token can currently be bought for approximately $0.0249 or 0.00000400 BTC on major exchanges. Live Stars has a total market cap of $990,922.00 and $25,651.00 worth of Live Stars was traded on exchanges in the last day.

Top 10 High Tech Stocks To Watch Right Now: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Aclaris Therapeutics (NASDAQ:ACRS) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $46.00.

Top 10 High Tech Stocks To Watch Right Now: Fifth Street Asset Management Inc.(FSAM)

Advisors’ Opinion:

  • [By Logan Wallace]

    Fifth Street Asset Management (OTCMKTS:FSAM) and U.S. Global Investors (NASDAQ:GROW) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

  • [By Logan Wallace]

    Fifth Street Asset Management (OTCMKTS: FSAM) and Triangle Capital (NYSE:TCAP) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Top 10 High Tech Stocks To Watch Right Now: Colliers International Group Inc. (CIGI)

Advisors’ Opinion:

  • [By Max Byerly]

    Colliers International Group Inc (NASDAQ:CIGI) (TSE:CIGI) shares hit a new 52-week high on Thursday . The stock traded as high as $80.95 and last traded at $80.95, with a volume of 604 shares trading hands. The stock had previously closed at $80.50.

  • [By Stephan Byrd]

    Colliers International Group (NASDAQ:CIGI) (TSE:CIGI) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

  • [By Ethan Ryder]

    Seritage Growth Properties Class A (NYSE: SRG) and Colliers International Group (NASDAQ:CIGI) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Colliers International Group (CIGI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Colliers International Gr (NASDAQ: CIGI) and Getty Realty (NYSE:GTY) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

  • [By Ethan Ryder]

    Shares of Colliers International Group Inc (NASDAQ:CIGI) (TSE:CIGI) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $79.75.

Top 10 High Tech Stocks To Watch Right Now: CIM Commercial Trust Corporation(CMCT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Crowd Machine (CURRENCY:CMCT) traded down 3.1% against the U.S. dollar during the 1-day period ending at 18:00 PM ET on February 2nd. One Crowd Machine token can currently be bought for approximately $0.0023 or 0.00000066 BTC on major cryptocurrency exchanges including Bancor Network, BitForex, Bittrex and HitBTC. During the last seven days, Crowd Machine has traded down 41.4% against the U.S. dollar. Crowd Machine has a total market capitalization of $1.09 million and approximately $553,701.00 worth of Crowd Machine was traded on exchanges in the last day.

  • [By Jack Delaney]

    CIM Commercial Trust Corp. (NYSE: CMCT) acquires, owns, and operates office properties in the United States.

    It has a portfolio of more than 100 buildings that is valued at a combined $25 billion, according to BizJournals.com.

  • [By Shane Hupp]

    CIM Commercial Trust (NASDAQ:CMCT) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Top 10 High Tech Stocks To Watch Right Now: Western Asset Municipal Partners Fund, Inc.(MNP)

Advisors’ Opinion:

  • [By Shane Hupp]

    Fiera Capital Corp grew its holdings in shares of Western Asset Municipal Partners Fnd Inc (NYSE:MNP) by 46.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 196,895 shares of the financial services provider’s stock after purchasing an additional 62,761 shares during the quarter. Fiera Capital Corp’s holdings in Western Asset Municipal Partners Fnd were worth $2,780,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Media stories about Western Asset Municipal Partners Fnd (NYSE:MNP) have been trending positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Western Asset Municipal Partners Fnd earned a media sentiment score of 0.38 on Accern’s scale. Accern also assigned media headlines about the financial services provider an impact score of 46.9266470312802 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top High Tech Stocks To Watch For 2019

Facebook’s (NASDAQ:FB) next big frontier won’t be in payments, virtual reality or artificial intelligence going by what the company’s recent quarterly earnings release revealed. At least not in the near term. According to CEO Mark Zuckerberg, video will be the next big thing for the social media giant much like how mobile played a pivotal role in growing the company.

With that being said, it seems that some investors may not be fully appreciating the massive opportunity that video presents to Facebook in terms of the potential impact that it could make on the income statement. In fact, some analysts have even suggested that video will be Facebook’s biggest risk because as users increasingly watch more videos, they spend less time looking at ads.

Top High Tech Stocks To Watch For 2019: FEI Company(FEIC)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Media headlines about FEI (NASDAQ:FEIC) have trended somewhat positive on Monday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. FEI earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the scientific and technical instruments company an impact score of 43.5801711111494 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top High Tech Stocks To Watch For 2019: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Max Byerly]

    Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

  • [By Joseph Griffin]

    Aclaris Therapeutics (NASDAQ:ACRS) received a $50.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 177.62% from the company’s current price.

  • [By Stephan Byrd]

    Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9638334424702 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Logan Wallace]

    News headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aclaris Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 47.0807215270757 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Top High Tech Stocks To Watch For 2019: Xenon Pharmaceuticals Inc.(XENE)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    TransEnterix, Inc. (NYSE: TRXC) rose 28.8 percent to $4.03 in pre-market trading after the company disclosed that it has received the FDA clearance for expanded indications for its Senhance Surgical System.
    Global Eagle Entertainment Inc. (NASDAQ: ENT) rose 15.6 percent to $2.30 in pre-market trading.
    Companhia Brasileira de Distribuição (NYSE: CBD) rose 13.2 percent to $24.20 in pre-market trading.
    ZTO Express (Cayman) Inc. (NYSE: ZTO) rose 12.2 percent to $21.65 in pre-market trading. Alibaba and Cainiao agreed to make strategic investment in ZTO Express of $1.38 billion.
    DHI Group, Inc. (NYSE: DHX) rose 10.8 percent to $2.05 in pre-market trading.
    Momo Inc. (NASDAQ: MOMO) shares rose 9.6 percent to $42.68 in pre-market trading after the company reported better-than-expected results for its first quarter and issued strong sales forecast for the second quarter.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares rose 9.1 percent to $6.00 in pre-market trading.
    Universal Display Corporation (NASDAQ: OLED) rose 8.4 percent to $108.00 in pre-market trading.
    Jupai Holdings Limited (NYSE: JP) shares rose 7 percent to $24.50 in pre-market trading after reporting Q1 results.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 5.9 percent to $10.61 in pre-market trading.
    Frontline Ltd. (NYSE: FRO) rose 5.9 percent to $5.04 in pre-market trading.
    Evogene Ltd. (NASDAQ: EVGN) rose 5.5 percent to $3.27 in pre-market trading after reporting Q1 results.
    Sears Holdings Corporation (NASDAQ: SHLD) rose 5.5 percent to $3.68 in pre-market trading after gaining 5.44 percent on Friday.
    Kitov Pharma Ltd (NASDAQ: KTOV) shares rose 5.4 percent to $2.16 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Alexander Bird]

    Here are last week’s top-performing penny stocks:

    Penny Stock Current Share Price Last Week’s Gain
    Ambow Education Holdings Ltd. (NYSE: AMBO) $5.70 77.11%
    Nano Dimension (Nasdaq: NNDM) $2.61 75.11%
    Destination Maternity Corp. (Nasdaq: DEST) $5.79 71.84%
    CLPS Inc. (Nasdaq: CLPS) $9.72 71.15%
    NII Holdings Inc. (Nasdaq: NIHD) $3.20 56.33%
    Viveve Medical Inc. (Nasdaq: VIVE) $3.78 51.98%
    Galectin Therapeutics Inc. (Nasdaq: GALT) $9.18 41.82%
    Apricus Biosciences Inc. (Nasdaq: APRI) $0.36 34.70%
    Polymet Mining Corp. (NYSE: PLM) $1.01 31.13%
    Xenon Pharmaceuticals Inc. (Nasdaq: XENE) $8.20 28.46%

    Many investors struggle with finding stocks with this sort of breakout potential because they don’t know where to look.

  • [By Lisa Levin] Gainers
    Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results.
    MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58.
    Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82.
    Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82.
    Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69.
    PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42.
    LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results.
    Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results.
    Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37.
    Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close

Top 10 Heal Care Stocks To Invest In Right Now

Celgene Corp. (NASDAQ:CELG) investors would probably like a few do-overs given the company’s stumbles over the past year. First, it suffered a key clinical-trial failure that forced it to ratchet back its long-term sales outlook. Then, the FDA sent it an embarrassing Refusal to File letter for its most-anticipated drug, ozanimod.

The setbacks have increased the pressure on the company to deliver a win, and fortunately, that win came in the form of positive pivotal-stage trial results for luspatercept, a drug that Celgene has licensed from Acceleron Pharma (NASDAQ:XLRN). On Thursday, the companies announced that luspatercept’s late-stage study in myelodysplastic syndromes (MDS) panned out, clearing the way for filings for approval next year. How big is this win for Celgene?

What’s going on

Luspatercept addresses chronic anemia in MDS by promoting the production of healthy red blood cells and regulating TGF-beta proteins involved in the late stages of creating red blood cells.

Top 10 Heal Care Stocks To Invest In Right Now: Computer Programs and Systems Inc.(CPSI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Millrace Asset Group Inc. acquired a new position in shares of Computer Programs & Systems, Inc. (NASDAQ:CPSI) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 45,000 shares of the company’s stock, valued at approximately $1,314,000. Millrace Asset Group Inc. owned about 0.32% of Computer Programs & Systems at the end of the most recent quarter.

  • [By Max Byerly]

    Computer Programs & Systems, Inc. (NASDAQ:CPSI) has received an average rating of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $30.80.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Computer Programs & Systems (CPSI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Computer Programs & Systems (NASDAQ: CPSI) and Perion Network Ltd Common Stock (NASDAQ:PERI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Top 10 Heal Care Stocks To Invest In Right Now: RPX Corporation(RPXC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Research Frontiers (NASDAQ: REFR) and RPX (NASDAQ:RPXC) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

  • [By Logan Wallace]

    Thompson Siegel & Walmsley LLC lifted its position in RPX Co. (NASDAQ:RPXC) by 32.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 787,377 shares of the business services provider’s stock after purchasing an additional 192,430 shares during the period. Thompson Siegel & Walmsley LLC owned about 1.58% of RPX worth $8,417,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Max Byerly]

    RPX (NASDAQ:RPXC) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday.

  • [By Dan Caplinger]

    Patent litigation abuse is a major problem in the tech industry, and policymakers have looked for ways to fight it. RPX (NASDAQ:RPXC) came up with a unique approach to patent protection involving purchases of various intellectual property to deter would-be plaintiffs from challenging ownership. Yet the market for those services hasn’t grown the way some had anticipated, and even after diversifying into legal discovery services, RPX saw little choice but to start pursuing strategic alternatives to come up with a future direction for its business.

Top 10 Heal Care Stocks To Invest In Right Now: Hertz Global Holdings Inc(HTZ)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern’s rankings:

    Get Hertz Global alerts:

    Trending Most Active Stock: Hertz Global Holdings, Inc. (HTZ) (nasdaqplace.com) Why is the 200 Simple Moving Average (SMA) so common for traders and analysts? Novavax, Inc. (NASDAQ:NVAX … (thestreetpoint.com) Hertz Global Holdings, Inc. (HTZ): That’s where you can keep the ball in your court (fintelegraph.com) Is Hertz Global Holdings Inc (NYSE:HTZ) A Financially Sound Company? (finance.yahoo.com) Hertz Global Hol Rises 1.95% on Heavy Volume: Watch For Potential Pullback (mysmartrend.com)

    A number of brokerages have commented on HTZ. ValuEngine upgraded shares of Hertz Global from a “hold” rating to a “buy” rating in a report on Thursday, June 7th. Zacks Investment Research downgraded shares of Hertz Global from a “hold” rating to a “sell” rating in a report on Tuesday, May 15th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $15.71.

  • [By Demitrios Kalogeropoulos]

    Hertz Global Holdings(NYSE:HTZ) shed 31% last month compared to a 2% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Nevro Corp. (NASDAQ: NVRO) fell 11.6 percent to $81.58 in pre-market trading after reporting wider-than-expected Q1 loss.
    Hertz Global Holdings, Inc. (NYSE: HTZ) shares fell 8.3 percent to $20.33 in pre-market trading after the company reported a wider-than-expected loss for its first quarter.
    Zillow Group, Inc. (NASDAQ: Z) fell 7.5 percent to $51.74 in pre-market trading. Zillow reported upbeat earnings for its first quarter, but issued weak sales guidance for the second quarter.
    Sanchez Energy Corporation (NYSE: SN) fell 7.2 percent to $3.11 in pre-market trading after reporting wider-than-expected Q1 loss.
    Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 5.5 percent to $4.14 in pre-market trading after rising 11.17 percent on Monday.
    Albemarle Corporation (NYSE: ALB) fell 5.1 percent to $95.00 in pre-market trading. Albemarle declared a quarterly dividend of $0.335 per share.
    Tata Motors Limited (NYSE: TTM) fell 4.8 percent to $23.80 in pre-market trading.
    Ormat Technologies, Inc. (NYSE: ORA) fell 4.5 percent to $57.14 in pre-market trading after reporting Q1 results.
    Kitov Pharma Ltd (NASDAQ: KTOV) shares fell 4.3 percent to $2.25 in pre-market trading after gaining 1.73 percent on Monday.
    51job, Inc. (NASDAQ: JOBS) shares fell 4.2 percent to $93 in pre-market trading after rising 3.55 percent on Monday

  • [By Dan Caplinger]

    Wall Street had another good session on Tuesday, with favorable earnings reports from some of the nation’s most successful technology companies helping to lift major benchmarks by 1% or more. Investors haven’t forgotten about some of the potential pitfalls that could derail the recovery, including both geopolitical and macroeconomic concerns. Yet traders seem to want to see the market test its all-time highs before deciding whether the correction could turn into a full-fledged bear market reversal. Some individual stocks, however, missed out on the good times. GoPro (NASDAQ:GPRO), Apellis Pharmaceuticals (NASDAQ:APLS), and Hertz Global Holdings (NYSE:HTZ) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Max Byerly]

    These are some of the news articles that may have impacted Accern’s rankings:

    Get Hertz Global alerts:

    Hertz Global Holdings, Inc (HTZ) CFO Thomas C. Kennedy Buys 15,000 Shares (americanbankingnews.com) Northcoast Research Weighs in on Hertz Global Holdings, Inc’s Q2 2018 Earnings (HTZ) (americanbankingnews.com) Hertz Global Target of Unusually High Options Trading (HTZ) (americanbankingnews.com) Edited Transcript of HTZ earnings conference call or presentation 8-May-18 12:00pm GMT (finance.yahoo.com) Hertz Sweeps 2018 FlyerTalk Awards (finance.yahoo.com)

    Several equities research analysts have issued reports on HTZ shares. Zacks Investment Research upgraded Hertz Global from a “sell” rating to a “hold” rating in a research report on Wednesday, January 17th. Macquarie upgraded Hertz Global from a “neutral” rating to an “outperform” rating in a research report on Thursday, January 18th. Goldman Sachs dropped their target price on Hertz Global from $15.00 to $13.00 and set a “sell” rating on the stock in a research report on Thursday, February 15th. Finally, ValuEngine downgraded Hertz Global from a “hold” rating to a “sell” rating in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $15.71.

Top 10 Heal Care Stocks To Invest In Right Now: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Todd Campbell]

    After disclosing that the Food and Drug Administration is asking for more information before signing off on a phase 1 study of its “Sleeping Beauty” CAR-T for leukemia and lymphoma, shares in Ziopharm Oncology (NASDAQ:ZIOP) were tumbling 17.7% at 3 p.m. EDT today.

  • [By George Budwell]

    Shares of the clinical-stage biotech Ziopharm Oncology (NASDAQ:ZIOP) rose by a healthy 16% last month,according toS&P Global Market Intelligence. What sparked this sizable rally?

  • [By Keith Speights]

    If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm’s share price has dropped more than 25% so far in 2018, while Celldex stock has plunged more than 80%.

  • [By Lisa Levin] Gainers
    Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday.
    Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00.
    SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday.
    Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40.
    Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance.
    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins.
    Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr

Top 10 Heal Care Stocks To Invest In Right Now: Tarena International, Inc.(TEDU)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Tuesday was a calm day on Wall Street, with several major benchmarks posting modest gains while others stayed closer to the unchanged mark. Market participants generally seemed ready to take a pause in trends over the past several days, as crude oil prices bounced back from their recent drop to climb above $65 per barrel while interest rates eased slightly lower. Yet despite a resilient market that largely avoided most downward pressure, some individual stocks weren’t as lucky. Carnival (NYSE:CCL) (NYSE:CUK), Tarena International (NASDAQ:TEDU), and Genesco (NYSE:GCO) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Steve Symington]

    Shares of Tarena International Inc. (ADR) (NASDAQ:TEDU) plummeted 22.1% on Tuesday after the China-based professional education services provider announced disappointing first-quarter 2018 results.

  • [By Max Byerly]

    K12 (NYSE: LRN) and Tarena International (NASDAQ:TEDU) are both small-cap consumer discretionary companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

  • [By Logan Wallace]

    Tarena International (NASDAQ: TEDU) and Aspen Group (NASDAQ:ASPU) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

  • [By Ethan Ryder]

    Tarena International (NASDAQ: TEDU) and TAL Education (NYSE:TAL) are both business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

Top 10 Heal Care Stocks To Invest In Right Now: Leggett & Platt, Incorporated(LEG)

Advisors’ Opinion:

  • [By Logan Wallace]

    California Public Employees Retirement System boosted its stake in shares of Leggett & Platt, Inc. (NYSE:LEG) by 2.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 413,255 shares of the company’s stock after purchasing an additional 10,689 shares during the period. California Public Employees Retirement System owned about 0.31% of Leggett & Platt worth $18,332,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Leggett & Platt (NYSE: LEG) and Hooker Furniture (NASDAQ:HOFT) are both consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Leggett & Platt (LEG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Candriam Luxembourg S.C.A. decreased its position in shares of Leggett & Platt, Inc. (NYSE:LEG) by 7.6% in the 1st quarter, HoldingsChannel reports. The fund owned 39,994 shares of the company’s stock after selling 3,289 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Leggett & Platt were worth $1,774,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    Shares of LEG Immobilien AG (FRA:LEG) have been assigned an average rating of “Buy” from the nineteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is €101.62 ($118.16).

Top 10 Heal Care Stocks To Invest In Right Now: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

  • [By ]

    Aimmune Therapeutics (AIMT) : “I do like it. That’s an important niche business. “

    Ingersoll-Rand (IR) : “I like Ingersoll-Rand. They work well at this phase in the cycle.”

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

Top 10 Heal Care Stocks To Invest In Right Now: Bravo Brio Restaurant Group Inc.(BBRG)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Media coverage about Bravo Brio Restaurant Group (NASDAQ:BBRG) has trended positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bravo Brio Restaurant Group earned a daily sentiment score of 0.39 on Accern’s scale. Accern also assigned media coverage about the restaurant operator an impact score of 45.847415840944 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 10 Heal Care Stocks To Invest In Right Now: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Max Byerly]

    Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

  • [By Stephan Byrd]

    Headlines about Aclaris Therapeutics (NASDAQ:ACRS) have been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aclaris Therapeutics earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.9638334424702 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Joseph Griffin]

    Aclaris Therapeutics (NASDAQ:ACRS) received a $50.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 177.62% from the company’s current price.

Top 10 Heal Care Stocks To Invest In Right Now: Cherokee Inc.(CHKE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Cherokee (NASDAQ:CHKE) released its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.11), RTT News reports. Cherokee had a negative return on equity of 13.63% and a negative net margin of 130.24%. During the same quarter last year, the business posted ($0.07) earnings per share.

  • [By Garrett Baldwin]

    Following the June FOMC meeting, silver prices are hovering at very attractive price levels. With interest rates heading higher, it’s going to be a very good time for silver hounds to buy on the dip and deliver incredible profits in the months ahead.Learn more right here.

    The Top Stock Market Stories for Thursday
    On Thursday, the European Central Bank held its meeting in Latvia to discuss the future of its quantitative easing program. The central bank of the world’s largest economic bloc said that it will likely end its quantitative easing program in December. This represents an extension beyond the current plan to end the stimulus program in September. ECB President Mario Draghi said the program would be reduced to 15 billion euros each month during the final three months of the year. Yesterday, the U.S. Federal Reserve raised interest rates for the second time in 2018. The central bank said that economic growth has been rising at a solid rate and hinted that it could raise rates two more times this year. Fed Chair Jerome Powell did raise an alarm on Wednesday after stating that companies are holding back on investment due to ongoing concerns about U.S. President Donald Trump’s trade policies. Trump is expected to decide this week on whether to proceed with tariffs on about $50 billion in Chinese goods. Trade tensions are heating up again. This morning, China announced it would call off its deal to avoid a trade war if the Trump administration proceeds with tariffs on Friday morning. Tomorrow, the Trump team will decide if it will hit China with tariffs on roughly $50 billion in goods.
    Stocks to Watch Today: ADBE, CMCSA, TSLA, MSFT
    Adobe Systems Inc. (Nasdaq: ADBE) will report earnings after the bell Thursday. The software giant is expected to report earnings per share of $1.54 on top of $2.15 billion in revenue. Insider buying is alive and well at Tesla Inc. (Nasdaq: TSLA). Chair and CEO Elon Musk purchased $25 million in company stock, according to a

  • [By Max Byerly]

    Cherokee (NASDAQ: CHKE) and J.Jill (NYSE:JILL) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Top 10 Heal Care Stocks To Own For 2018

Whether you’re ready for it or not, the marijuana industry is flowering before our eyes. In North America, cannabis research firm ArcView, in partnerships with BDS Analytics, has projected sales growth of 28% through 2021. If this estimate proves accurate, we could be looking at almost $25 billion in annual North American legal weed sales in just a few years.

All eyes are on Canada

Though the entire world has seemingly looked to the U.S. to lead the charge of cannabis progressivism, it’s stepped aside and allowed Canada to grab the reins. Despite 30 U.S. states having legalized marijuana in some capacity, the federal government and Attorney General Jeff Sessions have been unwavering on pot’s Schedule I classification — i.e., wholly illegal, prone to abuse, and having no recognized medical benefits.

Image source: Getty Images.

Top 10 Heal Care Stocks To Own For 2018: Arc Wireless Solutions Inc.(ARCW)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Watts Water Technologies (NYSE: WTS) and ARC Group WorldWide (NASDAQ:ARCW) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested small cap manufacturing and 3D printing service provider ARC Group WorldWide (NASDAQ: ARCW) as a short trade:

Top 10 Heal Care Stocks To Own For 2018: Computer Programs and Systems Inc.(CPSI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Computer Programs & Systems, Inc. (NASDAQ: CPSI) were down 31 percent to $27.00 after the company posted weaker-than-expected Q2 results.

Top 10 Heal Care Stocks To Own For 2018: Uni-Pixel, Inc.(UNXL)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Uni-Pixel (UNXL) manufactures electronic film products using its proprietary manufacturing process, UniBoss. This stock closed up 7.6% to $16.84 in Monday’s trading session.

    Monday’s Volume: 1.88 million

    Three-Month Average Volume: 1 million

    Volume % Change: 108%

    From a technical perspective, UNXL bounced sharply higher here right off its 50-day moving average of $15.89 with above-average volume. This stock looks to be forming a double bottom chart pattern at $14.91 to $15.16. If that bottom holds, then shares of UNXL could see a continuation of Monday’s upside action.

    Traders should now look for long-biased trades in UNXL as long as it’s trending above $15.16 or $14.91 and then once it sustains a move or close above Monday’s high of $17.53 with volume that hits near or above 1 million shares. If we get that move soon, then UNXL will set up to re-test or possibly take out its next major overhead resistance level at its 200-day moving average of $19.89.

  • [By Lisa Levin]

    Shares of UniPixel Inc (NASDAQ: UNXL) were down 22 percent to $1.63 after the company announced a public offering of newly issued shares of stock. UniPixel plans to offer 5.35 million shares of its own stock at a public offering price of $1.50 per share with the option for its underwriters to purchase up to an additional 802,500 shares.

  • [By Peter Graham]

    Small cap sensor film stockUniPixel Inc (NASDAQ: UNXL) reportedQ1 2017 earnings after the Thursday market close withshares falling both on Thursday and in afterhours trading. UniPixel is not well covered or known by analysts yet and this can make shares volatile. However and last September, we had suggested a long position in the stock based upon technicals by saying:

Top 10 Heal Care Stocks To Own For 2018: Canon, Inc.(CAJ)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    Miscellaneous shorts. Lamensdorf is also betting against Japanese printer and camera giant Canon (CAJ) since he believes the company still hasn’t figured out a way to compete with smartphones.

  • [By Dan Carroll]

    Nikon’s story is similar to what’s plaguing its Japanese rival, Canon (NYSE: CAJ  ) . Canon’s stock has nosedived by 20% year to date, but the stock’s recovered nearly 3% over the past month. Don’t let appearances fool you: The company slashed its full-year sales and profit forecasts back in July, as the worldwide camera market has slumped, and as smartphones continue to take over this aging niche. Canon’s route back to respectability looks like a treacherous climb.

Top 10 Heal Care Stocks To Own For 2018: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

Top 10 Heal Care Stocks To Own For 2018: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 10 Heal Care Stocks To Own For 2018: Helios and Matheson Analytics Inc(HMNY)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Helios and Matheson Analytics Inc. (Nasdaq: HMNY) is an information technology company that provides its clients predictive analytics. The company uses big data for most of its software and operates within the financial services, insurance, and healthcare industries. HMNY is up 278% YTD after it announced a strategic merger with a GPS application company, called RedZone Maps. RedZone is known for mapping crime in major cities. News of the merger sent HMNY climbing over 1,000% from $1.11 per share to $13.75 per share over the course of a week. The stock has since fallen to $5.23 per share as of Monday intraday.

  • [By Paul Ausick]

    The subscription service is controlled by Helios & Matheson Analytics Inc. (NASDAQ: HMNY), which owns about 81% of MoviePass stock.

    MoviePass CEO Mitch Lowe commented:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Peter Graham]

    Small cap analytics stock Helios and Matheson Analytics (NASDAQ: HMNY) is thethird most shorted stock on the NASDAQ with short interest of 54.30% according to Highshortinterest.com. Helios and Matheson Analytics is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology. The Company owns a majority interest in MoviePass Inc., the nation’s premier movie-theater subscription service.Other holdings include RedZone Map, a safety and navigation app for iOS and Android users, and a community-based ecosystem that features a socially empowered safety map app that enhances mobile GPS navigation using advanced proprietary technology.

  • [By Lisa Levin]

    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares dropped 32 percent to $6.87 after the company reported a common stock offering. The size of the offering was not disclosed. The company said that proceeds from the offering and warrants will be used to increase the company’s ownership stake in MoviePass.

Top 10 Heal Care Stocks To Own For 2018: Mastercard Incorporated(MA)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Visa Inc. (NYSE:V) and MasterCard (NYSE:MA) aren’t the only two players in the credit card and electronic payments space, but they are the biggest and best-known. Both Visa and MasterCard have extended their reach across the globe, and both have high expectations in their trajectories for future growth. Yet after a big push in the stock market that has sent both of these financial stocks to all-time highs, investors need to know which of the two leaders in the card industry is more deserving of their attention. Let’s take a closer look at Visa and MasterCard, comparing them using several different metrics to see which company’s shares are the better buy.

  • [By Matthew Cochrane]

    Keeping these statistics in mind, one can see how marrying these two concepts would be equivalent to finding the Holy Grail of payments. This is how Mastercard Inc (NYSE:MA), clearly one of the giants in the payments space, plans to capture market share and win more card issuer deals by making payments as safe and frictionless as possible.

  • [By John Ballard]

    Partnerships play a crucial role in extending PayPal’s reach to new customers and driving higher engagement. The deal with Visa(NYSE:V) opened the door for partnerships with Mastercard(NYSE:MA), Citigroup(NYSE:C), and Fidelity National Information Services (NYSE:FIS). As a result, more deals will come that will increase PayPal’s relevancy and ubiquity in the mobile payment landscape.

  • [By ]

    Card networks Visa (NYSE: V) and Mastercard (NYSE: MA), which benefit from the same tailwinds, aren’t much better, both with minuscule yields of 0.7%.

  • [By ]

    Mastercard Inc. (MA) announced this week that it plans to employ new blockchain specialists in an upcoming hiring round of 175 technology developers, Coindesk reported. The new tech hires will work from Mastercard’s Ireland office, where its research and development business, Mastercard Labs, is headquartered. The company said the aim of the new hires is to further the development of more efficient payment systems. Last September, Mastercard filed a patent for a blockchain system recording purchase orders, invoices and transaction data. Then in November, the company filed another application for blockchain-based solutions aimed at increasing the speed of transaction settlements.

  • [By WWW.GURUFOCUS.COM]

    For the details of Night Owl Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Night+Owl+Capital+Management%2C+LLC

    These are the top 5 holdings of Night Owl Capital Management, LLCVisa Inc (V) – 231,674 shares, 10.84% of the total portfolio. Shares reduced by 5.42%Mastercard Inc (MA) – 167,458 shares, 9.92% of the total portfolio. Shares reduced by 5.37%Alphabet Inc (GOOG) – 18,613 shares, 8.13% of the total portfolio. Shares reduced by 4.05%Amazon.com Inc (AMZN) – 15,674 shares, 7.32% of the total portfolio. Shares reduced by 3.17%The Priceline Group Inc (PCLN) – 6,970 shares,

Top 10 Heal Care Stocks To Own For 2018: Fox Factory Holding Corp.(FOXF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Fox Factory Holding Corp (NASDAQ: FOXF) was down 1.8 percent after posting a 2.16 percent rise over the day.

    Finally, Groupon Inc (NASDAQ: GRPN) gained 1.3 percent, continuing with the 3.85 percent spike it experienced on Friday trading.

Top 10 Heal Care Stocks To Own For 2018: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Shares of small cap natural compound and Cannabinoid extract stock Radient Technologies (CVE: RTI) have been taking off lately as the Company makes further progress commercializing its technology. The Company extracts natural compounds from a range of biological materials using microwave assisted processing (MAP), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield and cost. This technology is based on the selective and localized heating of the moisture present in all natural materials using microwaves as the energy source. This gives the Company a technological advantage and expertise in selectively depositing microwave energy into different parts of a biomass’ complicated chemical system form the core of our extraction advantage.

  • [By Bryan Murphy]

    It’s been a long time in the coming, but there’s no denying the tipping point has been reached — cannabinoids are the foundation for a whole new kind of medicine. And, the work-to-date turning cannabis into pharmaceuticals has been very encouraging.

    Problem: While the premise of cannabinoids as drugs has been validated, the science of creating large quantities of pure cannabinoids remains more ineffective than effective. Radient Technologies Inc (CVE:RTI) is about the change that, leveraging a means of extracting a lot of cannabinoid material from a source, and ensuring the highest-level of purity and quality.

    Radient Technologies manufactures natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics. Using a proprietary, patented technology, Radient’s products are superior in quality and purity while manufactured at a significantly lower cost than other methods thanks to superior yields and efficiency.

    To fully appreciate the science Radient has developed, however, one must understand the alternative methods currently employed.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated, and then over the course of several hours the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s far from ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, many undesirable components can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies uses an ingredient-extraction process called microwave assisted processing, or “MAP,” for short.

    Using its patented MAP process, Radient is able to selectiv

  • [By James E. Brumley]

    Some of the stories about how cannabis has changed lives for the better are nothing less than astounding. Take Illinois resident Darren Miller as an example. In 2015 Miller was diagnosed with lung cancer that was later deemed terminal. Miller underwent chemotherapy, without much hope, but also began using high-THC Indica cannabis oil. Miller is alive today, and arguably shouldn’t be.

    Then there’s Floridian Branden Petro. Not only does Petro suffer epilepsy, he commonly experiences seizures stemming from the condition. Nothing has stopped the seizures as quickly or effectively as 200 milligram worth of THC cannabis oil, administered as a nasal spray. Within 20 seconds of using it, it’s as of the seizure never happened.

    And there are millions of other such (and less dramatic) examples, all pointing in the same direction – cannabis has medical value on multiple fronts. Not facilitating its commercialization is a wasted opportunity.

    It’s a notion that’s far from lost on the people that have built Canadian-based Radient Technologies Inc (CVE:RTI) from the round up, recently inking a deal with supplier of cannabinoid extracts, Aurora Cannabis.

    It’s a real accolade. Aurora is one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.

    In most regards though, Radient Technologies is the big winner of the deal, as the partnership is apt to put its high-tech facility in full demand, helping to advance the advent of cannabis in all its potential glory.

    It’s a rather amazing science, really. Radient Technologies uses an ingredient-extraction process called microwave assisted proc